-
3 weeks ago | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Kathy Vuksanaj
With the advent of next-generation sequencing (NGS) technologies just over a decade ago, genomic information became available not only in labs, but also in clinical practice. Today, genomic testing is starting to play an important role in cancer patient care. Knowing the genetic makeup of a tumor can help oncologists determine the best therapeutic options for a patient, making genomic testing a growing part of precision medicine.
-
2 months ago | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
The U.S. biotech company Atalanta Therapeutics announced this week that it has raised $97 million in an oversubscribed Series B financing round led by the Swedish investment organization EQT Life Sciences and co-led by Sanofi Ventures and with participation from others. The financing will support the Phase 1 clinical development of two of Atalanta’s investigational RNA interference (RNAi) therapies for a specific form of epilepsy known as KCTN1-related epilepsy and Huntington’s disease.
-
2 months ago | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
The Swiss pharma giant Roche announced yesterday that the first approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), Elevidys, demonstrated statistically significant improvements in motor function in patients with DMD two years after treatment.
-
Jan 23, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
The Spanish contract development and manufacturing organization (CDMO) Viralgen and UK gene therapy developer Axovia Therapeutics announced yesterday that they have joined forces to boost the development and manufacturing of an investigational gene therapy to treat retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS). BBS is a rare genetic disease that affects different organs in the body.
-
Jan 21, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating its potentially first-in-class radiotherapy-activated nanoparticle candidate, JNJ-1900 (NBTXR3).
-
Jan 16, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
The U.S. biotech company Umoja Biopharma announced this week that it has raised $100 million in a Series C financing round co-led by Double Point Ventures and DCVC Bio, and supported by other new and existing investors. The proceeds will support the clinical development of Umoja’s in vivo CAR-T cell therapies –including its lead program UB-VV400 –for the treatment of cancer and autoimmune diseases.
-
Jan 14, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
Under the terms of the agreement, Regenxbio will receive a $110 million upfront payment at closing and is eligible for up to $700 million more, including $40 million in potential development and regulatory milestones and $660 million in potential sales milestones. Regenxbio will also receive royalties on net sales.
-
Jan 14, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin
The Swiss drug development company Windward Bio recently announced that it had officially launched with a $200 million Series A financing co-led by the leading global investors Novo Holdings, OrbiMed, Blue Owl Healthcare Opportunities, and others. “Our mission in starting Windward Bio is to discover and develop novel therapeutics for people living with serious immunological conditions,” said Luca Santarelli, Founder, CEO, and Chairman of Windward Bio in a press release.
-
Jan 9, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin |Rachel Arthur
The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, and commercialize up to five novel therapeutics for the treatment of amyotrophic lateral sclerosis (ALS). The companies will work with Alchemab’s antibody discovery platform, which uses samples from patients whose disease progresses much slower than normal.
-
Jan 7, 2025 | 
biopharma-reporter.com | Larissa Warneck-Silvestrin |Rachel Arthur
The U.S. biotech company Adcentrx Therapeutics announced yesterday that the first patient has been dosed in a Phase 1a/b trial testing its potential first-in-class antibody-drug conjugate, ADRX-0405, for the treatment of advanced solid tumors. This follows the FDA clearance for its IND application in October 2024. Antibody-drug conjugates are composed of an antibody attached to a cytotoxic payload. In the case of ADRX-0405, a humanized antibody is linked to a topoisomerase inhibitor payload.
